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Effects of Intraluminal Irradiation with
Holmium-166 for TIPS Stenosis:
Experimental Study in a Swine Model
Objective: We wanted to evaluate the effectiveness of intraluminal irradiation
with Holmium-166 (
166Ho) for reducing the pseudointimal hyperplasia (PIH) in the
transjugular intrahepatic portosystemic shunt (TIPS) tract in a swine model.
Materials and Methods: TIPS was performed in 12 domestic pigs, after the
creation of portal hypertension by intraportal injection of a mixture of N-butyl-2-
cyanoacrylate (NBCA) and lipiodol. Five pigs first underwent intraluminal irradia-
tion (30 Gy) in the parenchymal tract with using a 
166Ho solution-filled balloon
catheter, and this was followed by the placement of a nitinol stent in the TIPS
tract. For the seven control pigs, the balloon was filled with saline and contrast
media mixture. Two weeks later, follow-up portography and histological analysis
were performed.
Results: TIPS was successfully performed in all twelve pigs with achieving arti-
ficially induced portal hypertension. Portography performed two weeks after TIPS
showed the patent tracts in the TIPS tracts that were irradiated with 
166Ho (5/5,
100%), whereas either completely (5/6, 83.3%) or partially (1/6, 16.7%) occluded
TIPS were seen in the seven pigs of the nonirradiated control group, except in
one pig that experienced periprocedural death due to bleeding. Histological
analysis showed a statistically significant difference for the maximal PIH (irradiat-
ed: 32.8%, nonirradiated: 76.0%, p < 0.001) between the two groups.
Conclusion: Intraluminal irradiation with 30 Gy of 
166Ho for TIPS significantly
improved the TIPS patency in a swine model of portal hypertension during a 2-
week period of follow-up.
he transjugular intrahepatic portosystemic shunt (TIPS) procedure is
widely used for portal decompression in the setting of portal hyperten-
sion complicated by variceal hemorrhage or intractable ascites. However,
the follow-up data has demonstrated the limited long-term patency of TIPS, and the
resultant recurrent portal hypertension and rebleeding have occurred by one year in
up to 50 60% of the cases due to stenosis or occlusion of TIPS (1).
The previous clinical and experimental studies have reported that the causes of TIPS
malfunction were thrombosis during the early stage (within 2 weeks), and pseudointi-
mal hyperplasia (PIH) within the stented lumen of the hepatic parenchymal tract and
intimal hyperplasia within the outflow hepatic vein during the delayed stage (2 4).
Histologically, PIH, which is the main cause of stenosis, is initially made of loose
granulation tissue that’s formed by edema, myofibroblasts, neo-capillaries, collagen
fibers and inflammatory cells. Thereafter, it is thickened by the increased myofibrob-
lasts and collagen fibers. PIH in TIPS has known to be pathogenically similar to
myointimal hyperplasia after arterial stenting, and the over-proliferation that occurs in
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Tboth processes leads to luminal stenosis and stent failure
(3). The pathophysiology of PIH remains unclear, but
biliary leakage into the shunt, exposed liver parenchyma
and injured hepatic veins have been suggested as being the
initiators of hyperplasia (1, 4). However, their significance
is not unanimously accepted (5).
Irradiation with using external X-ray beam or intralumi-
nal brachytherapy was originally introduced for treating
the stent stenosis, following arterial myointimal hyperpla-
sia, that occurred after coronary or noncoronary arterial
intervention, and this type of irradiation treatment has
been successfully performed and reported upon (6 10).
Based on the similar proliferating processes of myointimal
hyperplasia and PIH, irradiation therapy was thought to be
useful for limiting the PIH in TIPS. However, its utility for
treating PIH in TIPS has not been validated. To the best of
our knowledge, there has been only one experimental
study by Lessie et al. that has evaluated the ability of
intraluminal irradiation to treat PIH in TIPS (11). They
applied irradiation for TIPS in a swine model and they
reported that a low-dose (15.2 Gy) of beta irradiation,
which has been commonly used for arterial stent
treatment, did not significantly reduce the development of
PIH in TIPS. They explained that this negative result could
be caused by the differences in the origin of the proliferat-
ing cells and their migration distance between myointimal
hyperplasia and PIH, and an insufficient irradiation dosage
was also a factor.
We hypothesized that administering a higher dose of
beta irradiation than the dose used in the coronary
intervention to the hepatic parenchymal tract at the time
of TIPS creation could inhibit hyperplasia and preserve
stent patency. Therefore, the purpose of this study was to
evaluate the ability of intraluminal irradiation with high-
dose (30 Gy) Holmium-166 (
166Ho) to reduce hyperplasia
and prevent stenosis of TIPS in a portal hypertension-
induced swine model.
MATERIALS AND METHODS
The experimental protocol of our study was used in all
12 domestic pigs (Yorkshire pigs, 2 months old and
weighing 15 20 kg each), after approval by the animal
care committees at this institution. All the pigs were in
good physical condition prior to the experiment. The
techniques and instrumentations used to create TIPS were
similar to that used for humans. This investigation aimed to
compare the results of the irradiated stent with the control
stent at a follow-up interval of two weeks. Five pigs of the
irradiated group underwent intraluminal irradiation of the
intrahepatic parenchymal tract during balloon inflation of
TIPS, whereas the seven pigs in the control group
underwent TIPS without irradiation.
166Ho for Irradiation Therapy
166Ho is a beta-emitting radioisotope. In our study, the
targeted therapeutic dose for TIPS was set at 30 Gy. Prior
to the experimental study in animals, we conducted an in
vitro pilot study to determine the optimal concentration
activity and exposure time of 
166Ho for acquisition of the
desired absorbed radiation dosage.
The liquid form of 
166Ho-(NO3)3 5H2O-DTPA was
provided by the Korea Atomic Energy Research Institute
(KAERI, Taejon, Korea). It was prepared by a neutron (n,
) reaction on abundant, non-radioactive 
165Ho that was at
a thermal flux state and by simple mixing the 
166Ho with
DTPA at room temperature. The produced 
166Ho had a
specific activity of 7.4 GBq mg
1 with a physical half-life
of 26.8 hour, and it emitted high energy  -particles with
maximum energies of 1.85 MeV (51%) and 1.77 MeV
(48%). A portion of  rays and K-shell X-rays were also
emitted. The range of absorbed  -particles distribution was
8.6 mm at maximum and 1.2 mm on average (12, 13).
GafChromic film (MD-55, Model Mo. 37 041, Lot
#941206, ISP Technologies Inc., Wayne, NJ) was used for
estimating the radiation dosage. A 
60Co teletherapy beam
and a 6 MV photon beam were used to obtain the dose
optical density calibration curves for the GafChromic film.
The exposed films were read by using a videodensitometer
(Model # WP700, Weellhofer Co., Schwarzenbruck,
Germany), with changing the radiation dosage. The
angioplasty balloon catheter (10 mm-diameter  4 cm-
length, Cook, USA) was filled with 3.16 mL of 
166Ho
solution (concentration activities: 1,850 MBq (50 mCi/mL)
and 3,700 MBq (100 mCi/mL)) and the balloon was
inflated to 3 atm pressure. The balloon was positioned in a
solid water phantom, and GafChromic film was placed and
adhered closely on the surface of balloon at an orthogonal
direction.
The exposure times for the desired absorbed dose (30
Gy) at the balloon surface were calculated with using the
different concentration activities (1,850 MBq and 3,700
MBq) (Table 1). Finally, the balloon was filled with 
166Ho at
a concentration activity of 1,850 MBq and it was inflated
to 3 atm for 4.5 minutes, delivering an absorbed surface
dosage of 30 Gy, which was the dose we decided to use in
the experimental study.
Creation of Portal Hypertension and TIPS
The animals were initially sedated with intramuscular
injections of 2 mL ketamine hydrochloride (Ketalar, Yuhan,
Seoul, Korea) and 2 mL xylazine hydrochloride (Rompun,
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intravenous administration of ketamine hydrochloride (0.01
cc/mL, 1 gtt/sec) during the procedure. The pigs were
placed in the supine position for flouoroscopy (Integris
2000, Philips, the Netherlands) with their necks were
rotated to the left. After making a skin incision (1 2 cm)
under sterile conditions, right external jugular venous
access was achieved by using an 18-gauge micropuncture
introducer (Green I.V. catheter , Greencross Medical Co.,
Seoul, Korea), a 0.035-inch Terumo guide wire (Terumo
Corporation, Tokyo, Japan) and a coaxial catheter-needle
set (RUPS 100, Cook, Charenton, France). A 10-Fr sheath
without an inner needle (Cook) was passed to the inferior
vena cava and advanced caudally into the right (or middle)
hepatic vein. After catheterization of the right hepatic vein,
a hepatic venogram and wedge portogram were performed
to guide the puncture of the right portal vein. A 16-gauge
Colapinto needle set (Cook) was introduced into the
hepatic vein. It was rotated ventrally and the tip was firmly
fixed against the vein wall. The needle and a 5-Fr catheter
were passed into the parenchyma toward the anticipated
region of the portal vein. After puncture of the right portal
vein, this was confirmed by aspiration of venous blood and
by injecting a small amount of contrast agent; the needle
was removed, and negative pressure was applied to the 5-
Fr catheter during slow withdrawal. Once the portal vein
was punctured, a 0.035-inch Terumo guide wire and a 5-Fr
angiographic catheter were advanced into the main portal
vein, and the pressure gradient between the portal vein and
the vena cava was measured using a Pharmaseal central
venous pressure monitor (Baxter Healthcare Corporation,
Valencia, CA). Portal venography was also obtained with
injecting contrast media by hand, and this demonstrated the
portal venous anatomy and its diameter.
Portal hypertension was artificially induced by intrapor-
tal injection of 0.02 mL of N-butyl-2-cyanoacrylate
(NBCA, sclerosing embolic agent, B-Brawn, Cook) mixed
with lipiodol (Lipiodol ultra-fluid, Guerbet, France) (1:3).
Under fluoroscopy, this mixture was injected until stasis of
the portal flow was achieved, and the portal pressure was
measured to confirm the occlusion. The injection volume
of the embolic mixture was approximately 1.5 2 mL.
After removal of all the needle parts except the superstiff
Amplatz-type guide wire and outer sheath, an angioplasty
balloon catheter (10 mm in diameter, 4 cm in length) was
used to dilate the hepatic parenchymal tract. Balloon
dilatation was performed at 3 atm for 4.5 minutes prior to
stent insertion. The balloon was filled with a solution of
166Ho in the irradiation group and with a mixture of
contrast media (Visipaque
TM 270, Amersham health, Cork,
Ireland) and saline (1:1) in the control group, respectively.
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Fig. 1. Follow-up studies done two weeks after TIPS with 
166Ho irradiation. 
A. Portography demonstrates good patency of the shunt without narrowing or occlusion. 
B. Microscopic examination (Masson-trichrome stain,  10) of the specimen obtained from the parenchymal tract of the patent stent
reveals that the luminal surface is lined by a relatively thin, uniform layer of pseudointimal hyperplasia. Pseudointimal hyperplasia (H) is
well delineated from the normal liver parenchymal layer (nl).
AB
Table 1. Exposure Times at the Surface, 0.5 mm and 1.0 mm
Away from the Balloon with Two Different
Concentration Activities of 
166Ho (1,850 MBq and
3,700 MBq) for the Desired Absorbed Dose (30 Gy)
Exposure Times with Concentration Activities
1,850 MBq 3,700 MBq
Surface 4.5 min 2.25 min
0.5 mm distance 06.75 min 3.38 min
1.0 mm distance 16.22 min 8.1 min0The irradiation source and its dosage were already
described in the previous section.
A 9-Fr sheath was advanced into the portal vein follow-
ing the slightly deflated balloon catheter. Finally, a nitinol
self-expandable stent (10 mm in diameter, 7 cm in length,
Niti-S TIPS stent, TaeWoong Medical Co., Koyang,
Korea), was placed in the parenchymal tract. The stent
position was intended to extend a short distance (about 1
cm) beyond the hepatic vein ostium into the inferior vena
cava in the cranial direction and approximately 1 2 cm or
more into the portal vein in the caudal direction. The stents
were successfully expanded without additional balloon
dilatation. Measurements of portal pressure and portogra-
phy were performed again immediately after stent deploy-
ment.
Follow-up Study
All 11 animals, except one pig that died of peritoneal
Park et al.
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Fig. 2. Follow-up studies done two weeks after TIPS without 
166Ho irradiation in the control group. 
A. Portography via the transjugular approach demonstrates the complete occlusion of the shunt. 
B. The corresponding gross specimen before removal of the stent wire shows marked ingrowth of fibrotic tissue (arrow) within the
parenchymal tract, which is in contrast to the lack of significant narrowing at both venous ends (H, hepatic venous end; P, portal venous
end). 
C. Transverse section (Masson-trichrome stain,  10) through the parenchymal tract of TIPS reveals the complete luminal occlusion with
the most superficial layer of fibrin (F), thick granulation tissue and the inflammatory reaction. The removed portions of the wires
(arrowheads) are seen as holes. These stent holes are seen adjacent to the normal parenchymal tissue (nl), which is clearly demarcated
from the PIH. 
D. Close-up (Masson-trichrome stain,  100) of the PIH shows numerous spindle-shaped myofibroblasts (arrows) and the abundant
collagen matrix.
CD
ABhemorrhage, tolerated the procedures well during the
follow-up period. The TIPS patency of the eleven cases
was evaluated using follow-up portal venography and
histological analysis two weeks after the procedures.
The animals were then tranquilized by an intramuscular
injection of 2 mL ketamine hydrochloride and 2 mL
xylazine hydrochloride without continuous intravenous
injection. Portal venography was obtained by introducting
a 5-Fr catheter into the portal vein via the jugular
approach. In two cases, in which the craniocaudal passage
of the catheter was disturbed by occlusion of the parenchy-
mal tract and the caudal part (portal vein portion) could
not be visualized, portal venography was performed via
the superior mesenteric vein that was exposed after an
abdominal wall incision (Fig. 3A). The extent and degree
of stent narrowing were assessed by comparing the
diameters of the stents immediately after and two weeks
after TIPS creation. Shunt occlusion was defined as the
absence of flow through the shunt, while shunt stenosis
was defined as narrowing of at least 50% of the stent
diameter.
The animals were then euthanized by an intravenous
injection of pentobarbital sodium. The TIPS shunt with a 2
cm rim of surrounding parenchymal tissue was cored out
and fixed in formalin solution for two weeks. Thereafter,
the stent were sectioned longitudinally at 5 mm thickness
intervals. The stent wires were carefully removed with use
of a dissecting microscope to minimize damage to the
underlying tissue. The cut specimens were processed in
paraffin and then transverse sections were obtained
perpendicular to the long axis of stent at each level of the
portal vein, the parenchymal tract and the hepatic vein.
Hematoxylin-eosin (H E) and Masson-trichrome staining
methods were used. On the histological examinations, the
granulation tissue from the stent to the luminal surface was
defined as the pseudointimal hyperplasia and its maximum
thickness was calculated for each animal as a percentage of
the estimated stent diameter. The histologic characteriza-
tion of the pseudointimal hyperplasia was also evaluated.
Statistical Analysis
For comparing the maximal PIH between the two
groups, the statistical analysis was performed with using
SPSS version 10.0 and two-sample t-tests; statistical signifi-
cance was set at p values < 0.01. Additionally, the mean
portal pressures measured in each pig before and after
NBCA embolization and also after TIPS stent insertion
were compared in order to confirm the successful creation
of portal hypertension and TIPS placement. 
RESULTS
Transjugular intrahepatic portosystemic shunt were
successfully deployed in all pigs, except in one case of
postprocedural death in the control group a day after TIPS
creation. The cause of death was intraperitoneal bleeding,
and this pig was excluded from the follow-up study.
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Fig. 3. Follow-up studies done two weeks after TIPS without 
166Ho irradiation in the control group. 
A. Portography via the superior mesenteric vein, which was exposed by a skin incision, shows partial occlusion of the shunt at the level
of parenchymal tract of TIPS. 
B. Microscopic cross section revealed a homogeneous layer of granulation tissue that’s composed of an abundant acellular matrix,
myofibroblasts and numerous inflammatory cells (between arrows) adjacent the stent wire (w).
ABFollow-up Venography
On follow-up venography, all of the five irradiated stents
were patent (5/5, 100%) (Fig. 1A). Meanwhile, the 5 TIPS
in the control group were completely occluded (5/6,
83.3%) (Fig. 2A) while the remaining TIPS was partially
occluded (1/6, 16.7%) (Fig. 3A). All of shunt stenoses or
occlusions developed in the hepatic parenchymal tract of
TIPS, while both the hepatic vein and portal vein portions
of the TIPS stents had relatively well-preserved lumens.
Histological Analysis
On histological analysis, the gross specimens in all cases
demonstrated partial or complete covering of the stent by
glistening white tissue (Fig. 2B). On portal venography, the
predominant site of stenosis was within the parenchymal
tract. Under microscopic examination, the granulation
tissue was proved to be PIH, which was composed of
numerous spindle-shaped myofibroblasts, extracellular
collagen matrix, undifferentiated mesenchymal cells and
inflammatory cells surrounding the stent wires (Figs. 1B,
2C, 2D, 3B). The specimens stained with both H-E and
Masson-trichrome revealed that the layers of pseudointi-
mal hyperplasia were sharply demarcated from the
surrounding hepatic parenchymal tissue layer. The
adjacent hepatic parenchyma appeared normal, except for
minimal protrusion into the luminal surface. Masson-
trichrome staining confirmed that the intercellular matrix
within the PIH was predominately composed of collagen.
In addition, a single cell layer that mimicked endothelial
cells was below various amounts of fibrin thrombus
deposits, which was the most superficial layer and this was
seen on the luminal surface. These findings showed similar-
ities with the PIH that occurred in human cases (3, 4). The
low-powered magnified histologic specimens obtained
from the irradiated stents revealed a thinner and more
uniform layer of hyperplasia (Fig. 1B) than that in the
nonirradiated control group (Table 2). No other histologic
difference, such as the composition and order of arrange-
ment, was evident between the two groups.
Microscopic transverse sections through the portal or
hepatic veins showed that the shunt lumen was continu-
ously lined with a single layer of endothelial cell.
Proliferation of smooth muscle cells was also noted
between the stent and luminal surface, and this
represented intimal hyperplasia. Compared with the PIH at
the parenchymal level, the intimal hyperplasia at the
venous levels had insignificant thickness and it was smooth
in contour. No bile staining or bile duct injury was seen in
any of the obtained specimens.
Statistical Analysis
The average maximum PIH, which was estimated as a
percentage of luminal stenosis per stent radius, was 32.8
13.27% in the irradiated group and 76.0 5.29% in the
control group, respectively. Two-sample t-test analysis of
the PIH in the irradiated versus the nonirradiated stents
demonstrated a statistically significant difference in the
maximum thickness of the PIH (p < 0.001).
The mean portal pressure estimated during the
procedure was 13.15 3.41 cmH2O and 26.78 5.80
cmH2O before and after the injection of NCBA, respec-
tively (mean increase = 13.63 cmH2O), and this immedi-
ately dropped back to 15.76 cmH2O after TIPS creation
(mean reduction = 11.02 cmH2O), demonstrating the
successful induction of portal hypertension by NCBA
embolization, and this was followed by satisfactory
reduction of the elevated portal pressure after stent
insertion with statistical significance (t-test, p < 0.01).
DISCUSSION
Irradiation therapy has been reported to be very
effective in preventing and reducing neointimal hyperpla-
sia following coronary or noncoronary arterial interven-
tion. The rationale for the use of irradiation to inhibit
neointimal hyperplasia is the high susceptibility of actively
proliferating cells to the lethal effects of ionizing radiation.
Experimental studies have shown that external irradiation
or low-dose (12 20 Gy) endovascular irradiation from
various sources, i.e., high energy  or  emitters such as
Iridium-192 (
192Ir) (6), Yttrium-90 (
90Y) (7), Phosphorus-32
Park et al.
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Table 2. Stent Patency and the Percentage of the Maximum
Pseudointimal Hyperplasia (PIH) within the
Parenchymal Tract of Each Animal
Animal No. Study  Stent  Maximum PIH 
Group Patency (%)
Pig 1 Control N/A N/A*
Pig 2 Control Completely occluded 73
Pig 3 Control Partially occluded 68
Pig 4 Control Completely occluded 83
Pig 5 Control Completely occluded 80
Pig 6 Control Completely occluded 77
Pig 7 Control Completely occluded 75
Pig 8 Irradiated Patent 21
Pig 9 Irradiated Patent 52
Pig 10 Irradiated Patent 27
Pig 11 Irradiated Patent 23
Pig 12 Irradiated Patent 41
Note. Maximum PIH (%) = thickness of PIH / estimated TIPS radius x 
100%, * Pig 1. Periprocedural death due to peritoneal bleeding at post-
TIPS 1st day.(
32P) (8) or 
166Ho (9), for an arterial stent during or after
angioplasty could significantly reduce the arterial myointi-
mal hyperplasia and as a result, increase the original
luminal patency. Our experimental study, based on the
similar proliferating processes between neointimal
hyperplasia and PIH, showed that the intraluminal irradia-
tion using 30 Gy 
166Ho during TIPS procedures significantly
reduced PIH in a swine model.
The standard local radiation dosages for inhibiting the
proliferative process in various settings have not been
established. In a previous experimental study with the
various activity levels (0.15 23  Ci) of 
32P, the dose-
related effects of the radiation source showed differential
response to the doses of continuous irradiation (the
intermediate activity level showed a more severe neointi-
mal response and greater luminal narrowing than that in
the nonradioactive stents), that is, a non-linear relation,
and this suggested a complex biological interaction of
endovascular radiation and vascular repair after stent
placement (10). Furthermore, the excess dosage of irradia-
tion is assumed to lead to adverse effects such as extensive
parenchymal injury as well as aggravation of thrombosis
by the increased fibrin deposits (14). In this experiment, an
absorbed radiation dose at the luminal surface of 30 Gy
with 4.5 minutes of dwell time was used, and this radiation
dose was thought to be a clinically applicable maximum
therapeutic dosage for vascular irradiation therapy (15,
16). This dosage was higher than the common dosage (less
than 20 Gy) used in neointimal hyperplasia (7, 9, 11).
Consequently, the use of this protocol did not induce the
radiation-associated changes such as endothelial prolifera-
tion or atypical fibroblasts in the vascular structures in any
cases, indicating there was acceptable tissue compatibility
to a high dosage of 
166Ho.
An ideal isotope for brachytherapy should have a high
specific activity with short range for avoiding unnecessary
irradiation to the adjacent normal tissue, and also achiev-
ing a uniform dose distribution over the treated area is a
must. To date, 
32P has been the most frequently used
radionuclide due to its relatively short half-time of 14.3
days, its limited range of 3 4 mm in tissue and no gamma
radiation (8, 11). In comparison with 
32P, the 
166Ho used in
this trial is another beta emitter with a specific activity of
7.4 GBq mg
1, a short physical half-life of 26.8 hours and
a short (1 2 mm) range of the absorbed  -particles distrib-
ution. These data suggest that 
166Ho is superior to 
32P from
the view of both the physical half-life and the activity
range. A few recent studies (9, 16, 17) that were
performed in vitro or in vivo with using 
166Ho as the
radiation source supported this suggestion. Joh et al. (16)
showed the 
166Ho administered through a balloon
angiocatheter in a tissue equivalent solid water phantom
delivered an adequate dose within a clinically allowable
dwell time, and so this avoided unnecessary irradiation of
the normal tissue. Hong et al. (17) demonstrated that 
166Ho-
DTPA in vivo showed simple radiolabelling, high
radiochemical stability (> 98%) and rapid urinary
excretion. Kim et al. (9) delivered 20 Gy of 
166Ho in a
porcine coronary stent restenosis model and the irradiated
group demonstrated a significantly decreased stenosing
area compared to the control group.
Pig is highly useful as an animal model for evaluating
new techniques related to human TIPS, and pigs have been
used in the previous related studies (18 20). Further, the
liver vascular anatomy of pig is similar with human. Also,
PIH in a swine model demonstrated remarkable similarities
in the histologic components and development sites to that
of human. On the other hand, to mimic the human
hemodynamic situations and to create the chronic portal
hypertension in animal models, various embolic agents
such as gelatin foam, polyvinyl alcohol, stainless steel coils
and ethiodized oil have been applied (18, 20, 21).
Unfortunately, chronic portal hypertension was success-
fully created in a dog model only, not in a swine model, in
which the increased portal pressure was transient and not
prolonged (20, 21). In our study, the portal hypertension
was artificially induced via intraportal injection of a NBCA
and lipiodol mixture (1:3); this is one of the most common
embolic materials used in other various procedures, includ-
ing treating vascular malformations and prior to lobectomy
(22, 23), and administering this material was done in a
single session. Our previous pilot study that used two pigs
was performed to evaluate the portal pressure after NBCA
embolization, and the results showed that the portal
hypertension was maintained for two weeks. Despite of
the small number of subjects as a limitation, from the
results of this pilot study, we can propose the possibility of
NBCA embolization for creating stable portal hyperten-
sion in a swine model. Based on the pilot study, all the
animals of this experiment were assumed to maintain
increased peripheral portal venous pressure, and this
resulted in preferential blood flow into the TIPS tract
rather than into hepatic sinusoids, at least for two weeks.
The follow-up period in this study was determined as
two weeks because the pig model provided a highly
accelerated rate of shunt stenosis within two to four weeks
after TIPS creation when compared to human (shunt
stenosis developed two weeks later in human) according to
Kichikawa et al. (18) and Lessie et al. (11). In our study,
the more rapid development of PIH in the control group
(within 2 weeks) may be due to that anticoagulation
therapy wasn’t given, the stent characteristics and the
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swines, as well as the NBCA, which has known to eventu-
ally induce parenchymal hypertrophy (23).
In this study, most of the stenoses were within the
parenchymal tract, but TIPS stenoses have actually
occurred in both hepatic veins and the parenchymal tracts
in clinical practices. This may be explained that the main
cause of TIPS stenoses in this study was PIH within the
hepatic parenchymal tract, and there was neither thrombo-
sis nor intimal hyperplasia within the vascular sites.
Our study has several limitations. First, the small and
uneven sample sizes of the control and irradiated groups
and short term follow-up period make it somewhat difficult
to conclude the value of 
166Ho in TIPS. The two weeks
follow-up period is not sufficient to induce cirrhotic
changes following the portal hypertension induced by
NBCA embolization, even though the portal hypertension
was sustained during the experimental period. Second, the
concrete evidence for the persistence of portal venous
hypertension was not sufficient. In our study, we found
that the follow-up portography demonstrated the reconsti-
tution of portal flow within the occluded portal vein in one
branch of five pigs. However, active evaluation of the
distal branches and collaterals was not performed. Liver
function tests, histologic confirmation of the parenchymal
tissue and long term follow-up of portal venous pressure
are needed to confirm the successful creation of chronic
portal venous hypertension in further studies. Third,
compared with the human cirrhotic liver, our animal model
still has a parenchymal difference such as periportal
fibrosis, although the artificial induction of portal
hypertension by embolic materials was done to mimic the
hemodynamic situation of cirrhosis. This may be followed
by the differences of response to radiation, biologic
interaction of repair and regeneration, and the stenosis
rates.
In conclusion, our study demonstrated a promising result
that the intraluminal irradiation using 30 Gy 
166Ho during a
TIPS procedure significantly reduced PIH in a swine model
of portal hypertension and this treatment improved TIPS
patency. However, the further studies are certainly
required to conclude the clinical feasibility of intraluminal
irradiation. 
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